• Please log in or register to access this feature.

Rheumatoid Arthritis

You have free access to this content

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases†

  1. Kevin Haynes1,*,
  2. Timothy Beukelman2,‡,
  3. Jeffrey R. Curtis2,§,
  4. Craig Newcomb1,
  5. Lisa J. Herrinton3,¶,
  6. David J. Graham4,
  7. Daniel H. Solomon5,‖,
  8. Marie R. Griffin6,
  9. Lang Chen2,
  10. Liyan Liu3,
  11. Kenneth G. Saag2,††,
  12. James D. Lewis1,‡‡,
  13. on behalf of the SABER Collaboration

Article first published online: 27 DEC 2012

DOI: 10.1002/art.37740

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 65, Issue 1, pages 48–58, January 2013

Additional Information

How to Cite

Haynes, K., Beukelman, T., Curtis, J. R., Newcomb, C., Herrinton, L. J., Graham, D. J., Solomon, D. H., Griffin, M. R., Chen, L., Liu, L., Saag, K. G., Lewis, J. D. and on behalf of the SABER Collaboration (2013), Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis & Rheumatism, 65: 48–58. doi: 10.1002/art.37740

Author Information

  1. 1

    University of Pennsylvania, Philadelphia

  2. 2

    University of Alabama at Birmingham

  3. 3

    Kaiser Permanente Northern California, Oakland

  4. 4

    FDA, White Oak, Maryland

  5. 5

    Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

  6. 6

    Vanderbilt University and Mid-South Geriatric Research Education and Clinical Center, VA Tennessee Valley Health Care System, Nashville

  1. ‡

    Dr. Beukelman has received consulting fees, speaking fees, and/or honoraria from Novartis and Genentech (less than $10,000 each) and research funding from Pfizer.

  2. §

    Dr. Curtis has received consulting fees, speaking fees, and/or honoraria from Pfizer, Bristol-Myers Squibb, Crescendo Bioscience, and Abbott (less than $10,000 each) and from Roche/Genentech, UCB, Centocor, Amgen, and the Consortium of Rheumatology Researchers of North America (CORRONA) registry (more than $10,000 each); he has received research grants from Pfizer, Bristol-Myers Squibb, Crescendo Bioscience, Abbott, Roche/Genentech, UCB, Centocor, CORRONA, and Amgen.

  3. Dr. Herrinton has received research contracts from Proctor & Gamble, Genentech, and Centocor.

  4. ‖

    Dr. Solomon has received consulting fees from CORRONA (more than $10,000) and research grants from Amgen, Abbott, and Eli Lilly and has served in uncompensated roles on clinical trials related to rheumatoid arthritis for the VA Health System and Pfizer.

  5. ††

    Dr. Saag has received consulting fees, speaking fees, and/or honoraria from Eli Lilly, Merck, Savient, Ardea Biosciences, Regeneron, URL Pharma, and Abbott (less than $10,000 each) and from Amgen (more than $10,000).

  6. ‡‡

    Dr. Lewis has received consulting fees, speaking fees, and/or honoraria from GlaxoSmithKline, Millennium Pharmaceuticals, Allos Therapeutics, Amgen, Pfizer, and Abbott (less than $10,000 each) and research grants from Centocor, Takeda, and Shire.

*University of Pennsylvania, Department of Epidemiology and Biostatistics, 713 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104

  1. †

    Statements in this article should not be construed as endorsement by the Agency for Healthcare Research and Quality (AHRQ), FDA, or US Department of Health and Human Services (DHHS).

  2. ‡

    Dr. Beukelman has received consulting fees, speaking fees, and/or honoraria from Novartis and Genentech (less than $10,000 each) and research funding from Pfizer.

  3. §

    Dr. Curtis has received consulting fees, speaking fees, and/or honoraria from Pfizer, Bristol-Myers Squibb, Crescendo Bioscience, and Abbott (less than $10,000 each) and from Roche/Genentech, UCB, Centocor, Amgen, and the Consortium of Rheumatology Researchers of North America (CORRONA) registry (more than $10,000 each); he has received research grants from Pfizer, Bristol-Myers Squibb, Crescendo Bioscience, Abbott, Roche/Genentech, UCB, Centocor, CORRONA, and Amgen.

  4. Dr. Herrinton has received research contracts from Proctor & Gamble, Genentech, and Centocor.

  5. ‖

    Dr. Solomon has received consulting fees from CORRONA (more than $10,000) and research grants from Amgen, Abbott, and Eli Lilly and has served in uncompensated roles on clinical trials related to rheumatoid arthritis for the VA Health System and Pfizer.

  6. ††

    Dr. Saag has received consulting fees, speaking fees, and/or honoraria from Eli Lilly, Merck, Savient, Ardea Biosciences, Regeneron, URL Pharma, and Abbott (less than $10,000 each) and from Amgen (more than $10,000).

  7. ‡‡

    Dr. Lewis has received consulting fees, speaking fees, and/or honoraria from GlaxoSmithKline, Millennium Pharmaceuticals, Allos Therapeutics, Amgen, Pfizer, and Abbott (less than $10,000 each) and research grants from Centocor, Takeda, and Shire.

Publication History

  1. Issue published online: 27 DEC 2012
  2. Article first published online: 27 DEC 2012
  3. Accepted manuscript online: 10 OCT 2012 08:31AM EST
  4. Manuscript Accepted: 2 OCT 2012
  5. Manuscript Received: 2 APR 2012

Funded by

  • AHRQ
  • FDA/DHHS. Grant Number: 1U18-HS-017919-0
  • AHRQ Centers for Education and Research on Therapeutics Program
  • NIH. Grant Numbers: 5KL2-RR-025776, AR- 053351, AHRQ grant R01-HS-018517, K24-DK07822806
  • University of Alabama at Birmingham Center for Clinical and Translational Science

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (133K)

REFERENCES

  • 1
    Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998; 317: 180–1.
  • 2
    Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692–701.
    Direct Link:
  • 3
    Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337–44.
  • 4
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [published erratum appears in JAMA 2006;295:2482]. JAMA 2006; 295: 2275–85.
  • 5
    Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009; 68: 1177–83.
  • 6
    Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644–53.
  • 7
    Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor α (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119–30.
    Direct Link:
  • 8
    Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011; 63: 1479–85.
    Direct Link:
  • 9
    Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, et al. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf 2011; 20: 1199–209.
    Direct Link:
  • 10
    Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 2007; 18: 561–9.
  • 11
    Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, et al, on behalf of the Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64: 1263–71.
    Direct Link:
  • 12
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3-18.
  • 13
    Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253–9.
    Direct Link:
  • 14
    Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 1074–8.
  • 15
    Lewis JD. Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease. Gut 2010; 59: 1586–7.
  • 16
    Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501–8.
  • 17
    Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886–95.
    Direct Link:
  • 18
    Wolfe F, Michaud K. The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433–9.
    Direct Link:
  • 19
    Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414–20.
  • 20
    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421–6.
  • 21
    Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130–5.
  • 22
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 3180–9.
    Direct Link:
  • 23
    Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121: 1080–7.
  • 24
    Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617–25.
  • 25
    Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121–5.
  • 26
    Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141: 1612–20.
  • 27
    Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al, for the CESAME Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621–8.e5.
  • 28
    Fraumeni JF Jr, Curtis RE, Edwards BK, Tucker MA. Introduction. In: Curtis RE, Freedman DM, Ron E, Ries LA, Hacker DG, Edwards BK, et al, editors. New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. NIH Publication No.: 05-5302. Bethesda, MD: National Cancer Institute; 2006. p. 1–7.
  • 29
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018–24.
  • 30
    Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007; 133: 769–79.
  • 31
    Agarwal SK, Maier AL, Chibnik LB, Coblyn JS, Fossel A, Lee R, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005; 53: 872–8.
    Direct Link:
  • 32
    Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 2007; 46: 1153–6.
  • 33
    Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011; 12: 204.
  • 34
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52–65.
  • 35
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.
  • 36
    Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268–74.
  • 37
    Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis 2011; 17: 1423–7.
    Direct Link:
  • 38
    Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 598–605.
    Direct Link:
View Full Article (HTML) Get PDF (133K)